---
title: "Legend Biotech Corporation (LEGN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LEGN.US.md"
symbol: "LEGN.US"
name: "Legend Biotech Corporation"
industry: "生物技術"
---

# Legend Biotech Corporation (LEGN.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.legendbiotech.com](https://www.legendbiotech.com) |

## Company Profile

傳奇生物科技公司通過其子公司運營，作為一家生物制藥公司，專注于在美國、中國和歐洲發現、開發、制造和商業化新型細胞療法，主要用于腫瘤及其他適應症。其主要產品候選藥物是 ciltacabtagene autoleucel，或稱 cilta-cel，這是一種用于治療多發性骨髓瘤（MM）的嵌合抗原受體（CAR-T）療法。該公司還擁有一系列早期階段的自體 CAR-T 產品候選藥物，針對多種癌症，包括非霍奇金淋巴瘤（NHL）、急性淋巴細胞白血病、胃癌、食道癌、胰腺癌、結直腸癌、肝細胞癌、小細胞肺癌和非小細胞肺癌。此外，它還開發了針對 B 細胞成熟抗原（BCMA）用于 MM 的異體伽馬δ CAR-T 和異體...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 80 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 74.75% |  |
| Net Profit YoY | 31.15% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.35 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.39B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 909.04M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -22.53% | E |
| Profit Margin | -26.37% | E |
| Gross Margin | 16.11% | D |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 74.75% | A |
| Net Profit YoY | 31.15% | B |
| Total Assets YoY | -1.32% | D |
| Net Assets YoY | -9.39% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -379.24% | D |
| OCF YoY | 74.75% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.53 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 40.96% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Legend Biotech Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-22.53%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-26.37%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "16.11%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "74.75%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.15%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.32%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.39%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-379.24%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "74.75%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "40.96%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -14.15 | 473/604 | - | - | - |
| PB | 3.35 | 250/604 | 6.43 | 5.77 | 4.36 |
| PS (TTM) | 3.73 | 77/604 | 9.88 | 7.89 | 4.85 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 10 | 59% |
| Overweight | 5 | 29% |
| Hold | 2 | 12% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.06 |
| Highest Target | 91.00 |
| Lowest Target | 21.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LEGN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LEGN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LEGN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.